Regulus Therapeutics (NASDAQ:RGLS)

CAPS Rating: 1 out of 5

Recs

2
Player Avatar zzlangerhans (99.85) Submitted: 11/4/2013 3:49:42 AM : Outperform Start Price: $7.03 RGLS Score: +10.70

Personally, I'm far from convinced that Regulus has dropped back to an appropriate valuation for their unproven, early stage micro RNA pipeline. Nevertheless, my red thumb was out of sync with my real life #zzporte position of 1000 shares bought at 7.5. The stock peaked over 12 before the company raised 46M from a dilutive financing at 9.5, which seems to have been their best strategic move in their brief existence. Now there's not much to do except wait for the share price to settle and see if Regulus can follow in the steps of Alnylam, Arrowhead, and Tekmira to outperform despite a lack of late stage pipeline accomplishments.

Featured Broker Partners


Advertisement